267 related articles for article (PubMed ID: 33409866)
1. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.
Lo Preiato V; Salvagni S; Ricci C; Ardizzoni A; Pagotto U; Pelusi C
Rev Endocr Metab Disord; 2021 Jun; 22(2):337-349. PubMed ID: 33409866
[TBL] [Abstract][Full Text] [Related]
2. A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma.
Singh V; Chu Y; Gupta V; Zhao CW
Cureus; 2020 Jun; 12(6):e8395. PubMed ID: 32637277
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
4. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.
Marchand L; Disse E; Dalle S; Reffet S; Vouillarmet J; Fabien N; Thivolet C; Cugnet-Anceau C
Acta Diabetol; 2019 Dec; 56(12):1239-1245. PubMed ID: 31423559
[TBL] [Abstract][Full Text] [Related]
5. Immune-checkpoint inhibitor-associated diabetes compared to other diabetes types - A prospective, matched control study.
Tittel SR; Laubner K; Schmid SM; Kress S; Merger S; Karges W; Wosch FJ; Altmeier M; Pavel M; Holl RW;
J Diabetes; 2021 Dec; 13(12):1007-1014. PubMed ID: 34275207
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.
Quandt Z; Young A; Anderson M
Clin Exp Immunol; 2020 May; 200(2):131-140. PubMed ID: 32027018
[TBL] [Abstract][Full Text] [Related]
7. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study.
Duvalyan E; Brondfield S; Rushakoff RJ; Anderson MS; Quandt Z
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730614
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
Fujiwara M; Shimizu M; Okano T; Maejima Y; Shimomura K
Front Public Health; 2023; 11():1264056. PubMed ID: 38106883
[TBL] [Abstract][Full Text] [Related]
11. Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.
Perdigoto AL; Deng S; Du KC; Kuchroo M; Burkhardt DB; Tong A; Israel G; Robert ME; Weisberg SP; Kirkiles-Smith N; Stamatouli AM; Kluger HM; Quandt Z; Young A; Yang ML; Mamula MJ; Pober JS; Anderson MS; Krishnaswamy S; Herold KC
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35925682
[TBL] [Abstract][Full Text] [Related]
12. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
Ning P; Liu S; Cao H
J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
[TBL] [Abstract][Full Text] [Related]
13. Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria.
Angelousi A; Ziogas DC; Siampanopoulou V; Mytareli C; Anastasopoulou A; Lyrarakis G; Gogas H
Diseases; 2024 Feb; 12(2):. PubMed ID: 38391787
[TBL] [Abstract][Full Text] [Related]
14. Type 1 diabetes induced by immune checkpoint inhibitors.
Zhang R; Cai XL; Liu L; Han XY; Ji LN
Chin Med J (Engl); 2020 Nov; 133(21):2595-2598. PubMed ID: 32842016
[TBL] [Abstract][Full Text] [Related]
15. A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors.
Deligiorgi MV; Trafalis DT
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108792
[TBL] [Abstract][Full Text] [Related]
16. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
Cho YK; Jung CH
Diabetes Metab J; 2023 Nov; 47(6):757-766. PubMed ID: 37482654
[TBL] [Abstract][Full Text] [Related]
17. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
[TBL] [Abstract][Full Text] [Related]
18. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.
Kiss I; Kuhn M; Hrusak K; Buchler T
ESMO Open; 2022 Jun; 7(3):100474. PubMed ID: 35576697
[TBL] [Abstract][Full Text] [Related]
19. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
Stamatouli AM; Quandt Z; Perdigoto AL; Clark PL; Kluger H; Weiss SA; Gettinger S; Sznol M; Young A; Rushakoff R; Lee J; Bluestone JA; Anderson M; Herold KC
Diabetes; 2018 Aug; 67(8):1471-1480. PubMed ID: 29937434
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus.
Liu J; Shi Y; Liu X; Zhang D; Zhang H; Chen M; Xu Y; Zhao J; Zhong W; Wang M
Transl Oncol; 2022 Oct; 24():101473. PubMed ID: 35905639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
